Lurbinectedin is a drug that is being developed for the treatment of various types of cancer. According to the sources provided, the current status of Lurbinectedin trials is as follows:

The drug is currently in Phase 3 clinical trials for the treatment of small cell lung cancer (SCLC) [1]. The trial is expected to enroll approximately 600 patients and is estimated to be completed in December 2021 [3].

In addition to SCLC, Lurbinectedin is also being evaluated in Phase 2 clinical trials for the treatment of other types of cancer, including ovarian cancer, endometrial cancer, and bladder cancer [1]. These trials are still ongoing and are currently recruiting participants [2].

Lurbinectedin is a novel drug that has shown promising results in preclinical studies and early-phase clinical trials. If the ongoing Phase 2 and Phase 3 trials are successful, it could potentially become a new treatment option for patients with various types of cancer.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://clinicaltrials.gov/ct2/results?cond=&term=lurbinectedin&cntry=&state=&city=&dist=
[3] https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c82382